日本人2型糖尿病患者を対象とした、セマグルチド週1回単剤療法または経口血糖降下薬との併用療法における安全性と有効性を比較する試験

基本情報

NCT ID

NCT02207374

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

601

治験依頼者名

Novo Nordisk A/S

概要

This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2 diabetes who are insufficiently controlled on diet/exercise therapy or OAD monotherapy. All subjects will continue their pre-trial treatment (diet and exercise therapy or OAD monotherapy in addition to diet and exercise therapy) during the trial.

対象疾患

介入

依頼者（Sponsor）